Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 4/20 | 0.31 |
| ▸ | RAB9A | P51151 | 4/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.31 |
| ▸ | MAPT | P10636 | 4/20 | 0.31 |
| ▸ | MEN1 | O00255 | 4/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | USP2 | O75604 | 2/20 | 0.31 |
| ▸ | GAA | P10253 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | PTP4A1 | Q93096 | 1/20 | 0.31 |
| ▸ | MIF | P14174 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL540753 | 0.90 | EP300 (0.37) | CYP2C9ALDH1A1PKMHTTTSHR | |
| SCHEMBL20261951 | 0.87 | EP300 (0.46) | CYP2C9NPSR1MAPTMEN1KMT2A | |
| SCHEMBL4135131 | 0.85 | CYP2C9 (0.40) | CYP2C9ALDH1A1PKMHTTTSHR | |
| SCHEMBL17859724 | 0.85 | CYP2C9 (0.40) | CYP2C9ALDH1A1PKMHTTTSHR | |
| SCHEMBL27679283 | 0.85 | CYP2C9 (0.40) | CYP2C9ALDH1A1PKMHTTTSHR | |
| SCHEMBL29045740 | 0.84 | CYP2C9 (0.40) | CYP2C9ALDH1A1PKMHTTTSHR | |
| SCHEMBL27913452 | 0.84 | CYP2C9 (0.37) | CYP2C9ALDH1A1TSHRNPC1RAB9A | |
| SCHEMBL29372874 | 0.83 | CYP2C9 (0.36) | CYP2C9ALDH1A1TSHR | |
| SCHEMBL5561382 | 0.82 | CYP2C9 (0.33) | CYP2C9ALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL8569025 | 0.80 | CYP2C9 (0.59) | CYP2C9ALDH1A1PKMHTTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100056626-A1 | COSMETIC PRODUCT FOR THE TREATMENT OF CICATRICIAL TISSUES | METIS S.R.L. (IT) | 2010-03-04 | — | — | US | claimed |
| EP-2081567-A1 | COSMETIC PRODUCT FOR THE TREATMENT OF CICATRICIAL TISSUES | Metis S.r.l. (IT) | 2009-07-29 | — | — | EP | claimed |
| WO-2008059541-A1 | COSMETIC PRODUCT FOR THE TREATMENT OF CICATRICIAL TISSUES | METIS S.R.L. (IT) | 2008-05-22 | — | — | WO | claimed |
| CN-113874459-B | Flexible photocurable cyanoacrylate compositions | 汉高股份有限及两合公司 | 2023-07-04 | — | — | CN | disclosed |
| US-9402762-B2 | Methods and devices for conduit occlusion | FEMASYS INC. | 2016-08-02 | — | — | US | disclosed |
| US-9220880-B2 | Methods and devices for delivery of compositions to conduits | FEMASYS INC. (US) | 2015-12-29 | — | — | US | disclosed |
| US-20150068531-A1 | METHODS AND DEVICES FOR CONDUIT OCCLUSION | FEMASYS INC. (US) | 2015-03-12 | — | — | US | disclosed |
| US-8726906-B2 | Methods and devices for conduit occlusion | FEMASYS INC. (US) | 2014-05-20 | — | — | US | disclosed |
| US-20130220335-A1 | Methods and Devices for Conduit Occlusion | FEMASYS INC. (US) | 2013-08-29 | — | — | US | disclosed |
| US-20130225977-A1 | Methods and Devices for Delivery of Compositions to Conduits | FEMASYS INC. (US) | 2013-08-29 | — | — | US | disclosed |
| US-8336552-B2 | Methods and devices for conduit occlusion | FEMASYS INC. (US) | 2012-12-25 | — | — | US | disclosed |
| WO-2008059541-A1 | COSMETIC PRODUCT FOR THE TREATMENT OF CICATRICIAL TISSUES | METIS S.R.L. (IT) | 2008-05-22 | — | — | WO | disclosed |
| EP-1838353-A2 | TOPICAL ADMINISTRATION PERMITTING PROLONGED EXPOSURE OF TARGET CELLS TO THERAPEUTIC AND PROPHYLACTIC NUCLEIC ACIDS | Introgen Therapeutics, Inc. (US) | 2007-10-03 | — | — | EP | disclosed |
| US-20070066552-A1 | Topical administration permitting prolonged exposure of target cells to therapeutic and prophylactic nucleic acids | INTROGEN THERAPEUTICS, INC. | 2007-03-22 | — | — | US | disclosed |
| WO-2006079014-A2 | TOPICAL ADMINISTRATION PERMITTING PROLONGED EXPOSURE OF TARGET CELLS TO THERAPEUTIC AND PROPHYLACTIC NUCLEIC ACIDS | INTROGEN THERAPEUTICS, INC. (US) | 2006-07-27 | — | — | WO | disclosed |
| US-6723114-B2 | CONTAINING ETHYLENE GLYCOL OXALATE COPOLYMER; BIOABSORBABLE OR BIODEGRADABLE; REDUCED REACTIONS AND FOREIGN BODY RESPONSES | POLY-MED, INC. | 2004-04-20 | — | — | US | disclosed |
| US-6699940-B2 | Cyanoacrylate-capped heterochain polymers and tissue adhesives and sealants therefrom | POLY MED, INC. | 2004-03-02 | — | — | US | disclosed |
| US-20030105256-A1 | Cyanoacrylate-capped heterochain polymers and tissue adhesives and sealants therefrom | POLY-MED, INC. | 2003-06-05 | — | — | US | disclosed |
| US-20020116026-A1 | Polyester/cyanoacrylate tissue adhesive formulations | POLY-MED, INC. | 2002-08-22 | — | — | US | disclosed |
| US-6299631-B1 | USEFUL AS TISSUE ADHESIVE/SEALANTS, HEMOSTATIC AGENTS, AND AS A MEANS FOR PATCHING OR ANASTOMIC COUPLING OF DAMAGED ORGANS; BIOABSORPTION | POLY-MED, INC. | 2001-10-09 | — | — | US | disclosed |